Finance
Molecular diagnostics company reports first quarter 2005 financial results
Published in Hepatitis Weekly, May 30th, 2005
Third Wave reported total revenues of $7.1 million and a net loss of $4.4 million, or ($0.11) per diluted share, for the quarter ended March 31, 2005, compared to total revenues of $15.3 million and net income of $2.8 million, or $0.07 per diluted share, for the same period of 2004.
The company reported clinical molecular diagnostic revenue of $3.1 million for the first quarter of 2005. U.S. clinical revenue increased 15% over the prior-year period. The sequential quarter-to-quarter decline in clinical revenue was due to the timing of large...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-05-30)
More Articles from Hepatitis Weekly
- Antiviral Therapy
Chronic hepatitis C responds well to interferon alfacon-1 combination therapy - Diagnostics
Reverse micelles detect hepatitis B virus polymerase gene point mutations - Gastroenterology
Antiviral therapy for chronic hepatitis C may reveal latent Crohn disease - Hepatitis C Therapy
Early response to therapy improves prospects for chronic hepatitis C patients - Virology
Combination therapy helps patients with hepatitis B and C virus coinfection - Acute Liver Failure
HLA homozygosity confers susceptibility to non-A non-B hepatitis - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
